Filing Flows › Viridian Therapeutics (VRDN) › Q2 2026 › vs Q2 2025
Viridian Therapeutics (VRDN) Q2 2026 vs Q2 2025 (year over year)
Viridian Therapeutics's revenue rose $209K (+279%) from $75K in Q2 2025 to $284K in Q2 2026.
Viridian Therapeutics, Q2 2026: revenue $284K (+279% year over year), net loss $127M, operating cash flow −$105M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $284K | $75K | $209K | +279% |
| Net loss | $127M | $101M | $26.4M | +26% |
| Costs & expenses | $127M | $107M | $20.6M | +19% |
| Operating costs | $127M | $107M | $19.7M | +18% |
| Interest & other, net | $851K | −$6.0M | $6.9M | — |
| Research & development | $71.6M | $86.6M | −$15.0M | -17% |
| SG&A | $55.0M | $20.2M | $34.8M | +172% |
| Operating cash sources | $127M | $101M | $26.4M | +26% |
| Depreciation & amortization | $117K | $113K | $4K | +4% |
| Share-based compensation | $17.0M | $10.8M | $6.1M | +57% |
| Working capital & other | $4.7M | $14.4M | −$9.7M | -67% |
| Cash used in operations | $105M | $75.4M | $30.0M | +40% |
| Net loss absorbed | $127M | $101M | $26.4M | +26% |
Questions
How much did Viridian Therapeutics's revenue grow year over year in Q2 2026?
Viridian Therapeutics's revenue rose $209K (+279%) from $75K in Q2 2025 to $284K in Q2 2026.